Clinical trials: Auto Stem Cell Transplant
High-risk Aggressive Lymphoma After Auto-HSCT
Maintenance Therapy Post-HSCT in High-risk Aggressive Lymphoma
Relapse after autologous hematopoietic stem cell transplantation (ASCT) is still challenging for high-risk aggressive lymphoma. This study was to investigate the efficacy and safety of maintenance therapy post-ASCT.
- Trial name
- NCT03695055
- Testing
- Maintenance therapy post-HSCT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fujian Medical University
Leukemia, Lymphocytic, Acute, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT
The clinical study of CART19 Cells treatment for MRD of B Cell Malignancies and then auto-HSCT
- Conditions
- Leukemia, Lymphocytic, Acute, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell
- Trial name
- NCT03685786
- Testing
- CART19 cell and auto-HSCT
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Second People's Hospital
Autologous Hematopoietic Stem Cell Transplantation, Diffuse Large B-cell Lymphoma
BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT
The purpose of this study is to evaluate the safety and efficacy of BUCY+VP-16 and BUCY myeloablative conditioning regimens in diffuse large B-cell lymphoma undergoing autologous hematopoietic stem cell transplantation.
- Conditions
- Autologous Hematopoietic Stem Cell Transplantation, Diffuse Large B-cell Lymphoma, Conditioning
- Trial name
- NCT03229616
- Testing
- Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16)
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Primary Central Nervous System Lymphoma, Autologous Hematopoietic Stem Cell Transplantation
BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT
The purpose of this study is to evaluate the safety and efficacy of BUCYE conditioning regimens in primary central nervous system lymphoma undergoing autologous hematopoietic stem cell transplantation.
- Conditions
- Primary Central Nervous System Lymphoma, Autologous Hematopoietic Stem Cell Transplantation, Conditioning
- Trial name
- NCT03733327
- Testing
- Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Nanfang Hospital, Southern Medical University
ALK-Positive Anaplastic Large Cell Lymphoma
Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL
To observe the safety, tolerability and clinical effects of crizotinib combined with etoposide capsule followed by autologous hematopoietic stem cell transplantation (Auto-HSCT) for patients with relapsed and refractory…
- Trial name
- NCT03707847
- Testing
- Crizotinib, Etoposide Capsule, Auto-HSCT
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Mingzhi Zhang
Delayed Platelet Engraftment, Neuroblastoma
Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma
The goal of this clinical trial is to learn if hetrombopag promotes platelet engraftment in neuroblastoma children undergoing autologous hematopoietic stem cell transplantation.
- Conditions
- Delayed Platelet Engraftment, Neuroblastoma, Autologous Hematopoietic Stem Cell Transplantation
- Trial name
- NCT06818916
- Testing
- Hetrombopag
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Children's Hospital
Autologous Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia
IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT
Autologous hematopoietic stem cell transplantation (Auto-HSCT) is an effective alternative to allogeneic HSCT for intermediate-risk acute myeloid leukemia (AML) without HLA-matched donors.
- Conditions
- Autologous Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Conditioning
- Trial name
- NCT02671708
- Testing
- Idarubicin（IDA）, Busulfan (BU), Cyclophosphamide (CY)
- Where
- China
- Volunteers
- 153 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Autologous Hematopoietic Stem Cell Transplantation, Conditioning
Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT
The purpose of this study is to evaluate the safety and efficacy of Melphalan and BUCY+VP-16 myeloablative conditioning regimens in multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
- Conditions
- Autologous Hematopoietic Stem Cell Transplantation, Conditioning, Multiple Myeloma
- Trial name
- NCT03385096
- Testing
- Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16)
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Auto Stem Cell Transplant for Lymphoma Patients
This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.
- Trial name
- NCT03125642
- Testing
- Etoposide, BCNU, AraC
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Effects of Chemotherapy
Consolidation Chemotherapy After Autologous Stem Cell Transplantation for Lymphoid Malignancies
To imporve the outcome of patients with relapsed/refractory lymphoma, we conduct a clinical trial to test the efficacy and feasibility of consolidation chemotherapy after autologous stem cell transplantation
- Trial name
- NCT02306837
- Testing
- Bu-CY-E
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Lymphoma, Hodgkin's Disease
Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease
High-dose chemotherapy followed by autologous (the patient's own) peripheral blood (circulating blood) stem cell (cells that divide to form white cells, red cells and cells that help clot) transplantation is a conventional…
- Trial name
- Rituxan+BEAM (NCT01702961)
- Testing
- Melphalan, Ara-C, VP-16
- Where
- 2 sites in United States
- Volunteers
- 75 people
- Sponsor
- Baylor College of Medicine